Norveġja -
Norveġiż -
Statens legemiddelverk
sotalol viatris 80 mg
viatris limited - sotalolhydroklorid - tablett - 80 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
strefen 8.75 mg/ dose
reckitt benckiser regulatory (scandinavia) a/s - flurbiprofen - munnspray, oppløsning med peppermynte/kirsebærsmak - 8.75 mg/ dose
Norveġja -
Norveġiż -
Statens legemiddelverk
ziprasidon actavis 40 mg
actavis group ptc ehf - ziprasidonhydroklorid - kapsel, hard - 40 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
ziprasidon actavis 20 mg
actavis group ptc ehf - ziprasidonhydroklorid - kapsel, hard - 20 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
ziprasidon actavis 60 mg
actavis group ptc ehf - ziprasidonhydroklorid - kapsel, hard - 60 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
ziprasidon actavis 80 mg
actavis group ptc ehf - ziprasidonhydroklorid - kapsel, hard - 80 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
aricept 5 mg
paranova as - donepezilhydroklorid - tablett, filmdrasjert - 5 mg
Norveġja -
Norveġiż -
Statens legemiddelverk
strefen 8.75 mg/ dose
reckitt benckiser healthcare (nordics) a/s - flurbiprofen - munnspray, oppløsning med honning/sitronsmak - 8.75 mg/ dose
Unjoni Ewropea -
Norveġiż -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
Norveġja -
Norveġiż -
Statens legemiddelverk
zeldox 80 mg
pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg